PMID- 31095037
OWN - NLM
STAT- Publisher
LR  - 20190516
IS  - 1473-5636 (Electronic)
IS  - 0960-8931 (Linking)
DP  - 2019 May 14
TI  - Nivolumab for patients with metastatic uveal melanoma previously untreated with
      ipilimumab: a single-institution retrospective study.
LID - 10.1097/CMR.0000000000000617 [doi]
AB  - OBJECTIVE: We evaluated the efficacy of nivolumab in patients with metastatic
      uveal melanoma previously untreated with ipilimumab. METHODS: We performed a
      retrospective study at the National Cancer Center Hospital in Tokyo, Japan, where
      nivolumab was approved 1 year earlier than ipilimumab. Clinical efficacy outcomes
      were determined by assessing best overall response according to the Response
      Evaluation Criteria in Solid Tumors (version 1.1), progression-free survival and 
      overall survival. RESULTS: Fourteen patients were analyzed; none had received any
      prior systemic therapies although eight had undergone transarterial
      chemoembolization. The median follow-up period was 15 months. The objective
      response and disease control rates were 7.1% and 42.9%, respectively (one partial
      response and five stable diseases). The median progression-free survival and
      overall survival were 10 (range, 4-105) and 60 (range, 5-105) weeks,
      respectively. Liver metastases in three patients were all programmed cell death-1
      ligand negative. Lower lactate dehydrogenase, development of vitiligo, and a
      neutrophil-to-lymphocyte ratio less than 5 at week 6 were associated with
      favorable progression-free survival and overall survival; of these, only a
      neutrophil-to-lymphocyte ratio less than 5 at week 6 was statistically
      significant. CONCLUSIONS: Even with the use of nivolumab before ipilimumab,
      metastatic uveal melanoma appears to remain refractory to nivolumab monotherapy. 
      However, because one patient in our cohort achieved an objective response, and
      the median overall survival exceeded 1 year, treatment strategies that
      incorporate anti-PD1 antibody should be further investigated. Whether a
      neutrophil-to-lymphocyte ratio less than 5 at week 6 is a favorable early
      on-treatment marker should be validated in larger cohorts.
FAU - Namikawa, Kenjiro
AU  - Namikawa K
AD  - Departments of Dermatologic Oncology.
FAU - Takahashi, Akira
AU  - Takahashi A
AD  - Departments of Dermatologic Oncology.
FAU - Mori, Taisuke
AU  - Mori T
AD  - Pathology and Clinical Laboratories.
FAU - Tsutsumida, Arata
AU  - Tsutsumida A
AD  - Departments of Dermatologic Oncology.
FAU - Suzuki, Shigenobu
AU  - Suzuki S
AD  - Ophthalmic Oncology, National Cancer Center Hospital, Tokyo, Japan.
FAU - Motoi, Noriko
AU  - Motoi N
AD  - Pathology and Clinical Laboratories.
FAU - Jinnai, Shunichi
AU  - Jinnai S
AD  - Departments of Dermatologic Oncology.
FAU - Kage, Yuta
AU  - Kage Y
AD  - Departments of Dermatologic Oncology.
FAU - Mizuta, Haruki
AU  - Mizuta H
AD  - Departments of Dermatologic Oncology.
FAU - Muto, Yusuke
AU  - Muto Y
AD  - Departments of Dermatologic Oncology.
FAU - Nakano, Eiji
AU  - Nakano E
AD  - Departments of Dermatologic Oncology.
FAU - Yamazaki, Naoya
AU  - Yamazaki N
AD  - Departments of Dermatologic Oncology.
LA  - eng
PT  - Journal Article
DEP - 20190514
PL  - England
TA  - Melanoma Res
JT  - Melanoma research
JID - 9109623
EDAT- 2019/05/17 06:00
MHDA- 2019/05/17 06:00
CRDT- 2019/05/17 06:00
PHST- 2019/05/17 06:00 [entrez]
PHST- 2019/05/17 06:00 [pubmed]
PHST- 2019/05/17 06:00 [medline]
AID - 10.1097/CMR.0000000000000617 [doi]
PST - aheadofprint
SO  - Melanoma Res. 2019 May 14. doi: 10.1097/CMR.0000000000000617.